{
    "title": "Glycyrrhizin (Licorice) vs Liver Damage",
    "inventor_name": null,
    "publication_year": null,
    "device_name": "Glycyrrhizin formulation (injectable/oral)",
    "goal": "Protect the liver from acute and chronic injury",
    "problem_addressed": "Liver damage caused by toxins, viral infection, inflammatory mediators, and ischemia-reperfusion",
    "concept_summary": "Glycyrrhizin, a triterpene glycoside extracted from licorice root, exhibits hepatoprotective activity through anti-inflammatory, antioxidant, and immunomodulatory mechanisms. Formulations have been developed for injectable, oral, rectal, intranasal and subcutaneous delivery to overcome its low membrane permeability and gel-forming tendency. In animal models (CCl_4, acetaminophen, concanavalin-A, ischemia-reperfusion) and limited clinical studies, glycyrrhizin reduced serum transaminases, suppressed pro-inflammatory cytokines, inhibited iNOS and HMGB1 expression, and improved cellular immunity.",
    "detailed_description": null,
    "category": "Medical & Dental Technologies",
    "principles": [
        "Anti-inflammatory",
        "Antioxidant",
        "Cytokine modulation",
        "HMGB1 inhibition",
        "iNOS down-regulation",
        "Membrane stabilization"
    ],
    "scientific_domains": [
        "Pharmacology",
        "Hepatology",
        "Immunology",
        "Biochemistry"
    ],
    "mechanisms_of_action": [
        "Inhibition of high-mobility group box 1 (HMGB1) release from Kupffer cells",
        "Suppression of inducible nitric oxide synthase (iNOS) expression",
        "Reduction of tumor necrosis factor-alpha (TNF-alpha) and other pro-inflammatory mediators",
        "Scavenging of reactive oxygen species and reduction of lipid peroxidation",
        "Reversal of altered fatty-acid metabolism"
    ],
    "materials": [
        "Glycyrrhizin (glycyrrhizic acid)",
        "Monoammonium glycyrrhizinate",
        "Glycine",
        "L-cysteine",
        "Solubility agents (e.g., cyclodextrins, polysorbates)",
        "Absorption-enhancing agents (e.g., surfactants, permeation enhancers)"
    ],
    "energy_sources": [],
    "inputs": [
        "Glycyrrhizin (dose-dependent)",
        "Vehicle solution (glucose, saline, etc.)"
    ],
    "outputs": [
        "Lower serum ALT/AST levels",
        "Reduced hepatic HMGB1, iNOS, and inflammatory cytokine levels",
        "Improved liver histology",
        "Enhanced cellular immunity"
    ],
    "claimed_performance": "Significant reduction of ALT/AST (up to 70 % in some animal models) and attenuation of toxin-induced liver injury; clinical improvement of liver function in children with infectious mononucleosis-related liver impairment.",
    "experimental_evidence": "Multiple peer-reviewed studies in mice and rats (CCl_4, acetaminophen, Con A, ischemia-reperfusion) and a randomized clinical trial in children demonstrate hepatoprotective effects of glycyrrhizin.",
    "replication_status": "Effect replicated across several independent animal studies and at least one clinical trial.",
    "keywords": [
        "glycyrrhizin",
        "licorice",
        "hepatoprotection",
        "anti-inflammatory",
        "HMGB1",
        "iNOS",
        "acetaminophen toxicity",
        "CCl_4",
        "drug formulation"
    ],
    "related_technologies": [
        "Other hepatoprotective phytochemicals (silymarin, curcumin)",
        "Anti-inflammatory biologics",
        "Nanoparticle drug delivery systems"
    ],
    "controversy_level": "low",
    "confidence_score": 0.9,
    "practicability_score": 0.8,
    "fringe_score": 0.1,
    "evidence_strength": 0.7,
    "risk_score": 0.2,
    "trl_estimate": 6,
    "source_urls": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17603270",
        "http://www.ncbi.nlm.nih.gov/pubmed/17917259",
        "http://www.ncbi.nlm.nih.gov/pubmed/4029553",
        "http://www.ncbi.nlm.nih.gov/pubmed/25032255",
        "http://link.springer.com/article/10.1007%2Fs00011-009-0024-8",
        "http://www.hindawi.com/journals/bmri/2014/872139/",
        "http://science.naturalnews.com/pubmed/2859634.html",
        "http://science.naturalnews.com/pubmed/18223035.html"
    ],
    "organizations": [
        "NTXTechnology",
        "Japanese medical research institutions"
    ],
    "applications": [
        "Treatment of acute and chronic liver disease",
        "Adjunct therapy for drug-induced hepatotoxicity",
        "Supportive care in viral hepatitis and autoimmune hepatitis"
    ],
    "limitations": [
        "Low oral membrane permeability",
        "Gel formation in high-concentration aqueous solutions",
        "Requirement for injection in many current formulations",
        "Limited large-scale clinical data"
    ],
    "open_questions": [
        "Can oral formulations achieve therapeutic plasma levels?",
        "What are the long-term safety profiles in diverse patient populations?",
        "How does glycyrrhizin interact with other hepatoprotective drugs?"
    ],
    "red_flags": [],
    "evidence_quotes": [
        "\"Glycyrrhizin attenuated the increase in serum aminotransferase activities and reduced hepatic malondialdehyde levels in CCl_4-treated mice.\"",
        "\"Glycyrrhizin significantly prevented acetaminophen-induced liver damage as indicated by ALT and AST activity.\"",
        "\"Glycyrrhizin suppressed iNOS mRNA and protein expression in concanavalin-A-induced hepatitis.\"",
        "\"Serum HMGB1 levels were significantly blunted in the glycyrrhizin-treated group compared with controls after ischemia-reperfusion injury.\"",
        "\"Children receiving compound glycyrrhizin injection showed greater improvement in ALT, AST and cellular immunity than controls (p<0.01).\""
    ]
}